Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IA5O
|
|||
| Former ID |
DIB011261
|
|||
| Drug Name |
GSK-2241658A
|
|||
| Synonyms |
NY-ESO-1 ASCI (melanoma), GSK; Recombinant NY-ESO-1 antigen immunotherapeutic vaccine (melanoma), GlaxoSmithKline; 2241658A
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cancer/testis antigen 1 (NY-ESO-1) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.